"Yeah the IND clearance from the FDA is a critical validation step."...........for Cynata's ongoing commercial partnering activities. No ongoing partnering activities, no trial BECAUSE.....you guessed it, you need money to do FDA trials AND lots of it.
The information presented assumes you can work out for yourself that the trial isn't free. Cynata is also not explaining that whilst you read their announcements, you must continue to inhale and exhale or you will expire.
I think you are just not wanting to see it. Coupled with they not wanting you to see it.
Let's go back a bit.....
"Cynata and Fujifilm intend that Fujifilm will have first rights to manufacture clinical and commercial requirements for Cymerus therapeutic MSC products. In addition, and in recognition of the progress made by Fujifilm, Cynata will pay Fujifilm a proportion of any upfront licence fee received by Cynata if Cynata approves main terms of a GvHD licence agreement with certain third parties within the next 6 months. "
https://www.prnewswire.com/news-releases/cynata-enters-into-a-new-strategic-partnership-with-fujifilm-301388606.html
30 September 2021.
That 6 months is now 13 months.
It looks to me that the hole of 'progress' with GVHD just keeps getting dug deeper and deeper.
No money, no trial. It's that simple.
As I've said before, think about the 'sales pitch' to prospective partners that are CRITICAL to this trial progressing. Wow - just wow.
Candidates enrolled by the end of the year? Planning for the trial has commenced? Get them to add 'color' to these two little gems.
- Forums
- ASX - By Stock
- What questions do holders want asked at the AGM?
CYP
cynata therapeutics limited
Add to My Watchlist
9.68%
!
17.0¢

"Yeah the IND clearance from the FDA is a critical validation...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
17.0¢ |
Change
0.015(9.68%) |
Mkt cap ! $38.41M |
Open | High | Low | Value | Volume |
15.5¢ | 17.0¢ | 15.5¢ | $47.10K | 289.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 16.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.0¢ | 23813 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.165 |
4 | 47240 | 0.155 |
4 | 161673 | 0.150 |
1 | 5000 | 0.145 |
2 | 45000 | 0.140 |
Price($) | Vol. | No. |
---|---|---|
0.170 | 18813 | 2 |
0.175 | 55250 | 1 |
0.180 | 62619 | 3 |
0.185 | 35990 | 1 |
0.195 | 19300 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online